Tocagen believes the immune system can be safely activated to fight the patient’s cancer. Driven by this vision, we are using our cancer-selective gene therapy technology to develop first-in-class, broadly applicable, product candidates designed to activate a patient’s immune system against their own cancer from within.
Tocagen is advancing its lead cancer-selective gene therapy, Toca 511 & Toca FC, for patients with brain and bladder cancer.
Tocagen is advancing a broadly applicable, cancer-selective gene therapy platform that is designed to deliver therapeutic genes into the DNA of cancer cells and activate a patient’s immune system against their own cancer from within.
Tocagen is committed to fighting cancer. We have multiple clinical trials ongoing with our lead cancer-selective gene therapy product candidate, Toca 511 & Toca FC.
Tocagen offers investors several resources to learn more about the company, including press releases, presentations and scientific publications.
Tocagen Reports Third Quarter 2019 Financial Results and Business Updates
Interested in following our progress? Subscribe below.